Overall, semaglutide therapy results in lean mass loss that constitutes about 39% of total weight reduction, with appendicular skeletal muscle volume declining by 910% over 2 years, effects that are particularly pronounced in older adults and those with baseline sarcopenia
Comparing 50 units across different GLP-1 medications Semaglutide is not the only GLP-1 receptor agonist on the market
Key Wegovy lawsuit takeaways Thousands of people have reported suffering serious side effects and complications after taking Wegovy
While long-term markers still matter, post-meal spikes often go Read More Sleep and Diabetes: Why the 2025 Guidelines Say Its Time to Prioritize Rest Dec 25, 2025 Articles, Blood Glucose Control, Blood Glucose Control, Diabetes, Diet & Nutrition, Physical Activity, Type 2 Diabetes, Type 2 Diabetes 2,732 views Sleep and diabetes are more connected than ever before